Large-scale drug screens support precision medicine

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The major challenge underlying the emerging precision medicine initiative is to make links between cancer subsets and drugs that can be used to guide treatment of individual patients, leading to improved outcomes and decreased toxicity. Seashore-Ludlow and colleagues support this effort by reporting measurements of responses of 664 adherent cancer cell lines to 70 FDA-approved drugs, 100 experimental compounds, and 311 small-molecule probes. They use a novel Annotated Cluster Multidimensional Enrichment algorithm to identify drug mechanisms of action, molecular markers of response, responsive cancer subtypes, and compounds that produce synergistic cell inhibition.

Original languageEnglish (US)
Pages (from-to)1130-1132
Number of pages3
JournalCancer Discovery
Volume5
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Precision Medicine
Pharmaceutical Preparations
Neoplasms
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Large-scale drug screens support precision medicine. / Gray, Joe; Mills, Gordon.

In: Cancer Discovery, Vol. 5, No. 11, 01.11.2015, p. 1130-1132.

Research output: Contribution to journalArticle

@article{1f14f87baaf34d10b5ee316095977bad,
title = "Large-scale drug screens support precision medicine",
abstract = "The major challenge underlying the emerging precision medicine initiative is to make links between cancer subsets and drugs that can be used to guide treatment of individual patients, leading to improved outcomes and decreased toxicity. Seashore-Ludlow and colleagues support this effort by reporting measurements of responses of 664 adherent cancer cell lines to 70 FDA-approved drugs, 100 experimental compounds, and 311 small-molecule probes. They use a novel Annotated Cluster Multidimensional Enrichment algorithm to identify drug mechanisms of action, molecular markers of response, responsive cancer subtypes, and compounds that produce synergistic cell inhibition.",
author = "Joe Gray and Gordon Mills",
year = "2015",
month = "11",
day = "1",
doi = "10.1158/2159-8290.CD-15-0945",
language = "English (US)",
volume = "5",
pages = "1130--1132",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Large-scale drug screens support precision medicine

AU - Gray, Joe

AU - Mills, Gordon

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The major challenge underlying the emerging precision medicine initiative is to make links between cancer subsets and drugs that can be used to guide treatment of individual patients, leading to improved outcomes and decreased toxicity. Seashore-Ludlow and colleagues support this effort by reporting measurements of responses of 664 adherent cancer cell lines to 70 FDA-approved drugs, 100 experimental compounds, and 311 small-molecule probes. They use a novel Annotated Cluster Multidimensional Enrichment algorithm to identify drug mechanisms of action, molecular markers of response, responsive cancer subtypes, and compounds that produce synergistic cell inhibition.

AB - The major challenge underlying the emerging precision medicine initiative is to make links between cancer subsets and drugs that can be used to guide treatment of individual patients, leading to improved outcomes and decreased toxicity. Seashore-Ludlow and colleagues support this effort by reporting measurements of responses of 664 adherent cancer cell lines to 70 FDA-approved drugs, 100 experimental compounds, and 311 small-molecule probes. They use a novel Annotated Cluster Multidimensional Enrichment algorithm to identify drug mechanisms of action, molecular markers of response, responsive cancer subtypes, and compounds that produce synergistic cell inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84946203551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946203551&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-0945

DO - 10.1158/2159-8290.CD-15-0945

M3 - Article

C2 - 26526695

AN - SCOPUS:84946203551

VL - 5

SP - 1130

EP - 1132

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 11

ER -